PIK3CA testing and treatment patterns in hormone receptor–positive, HER2-negative metastatic breast cancer in a United States health network
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction Targeted treatments are approved and in development for PIK3CA -mutated, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer. Current clinical guidelines recommend biomarker testing. This retrospective cohort study characterized PIK3CA mutation testing and treatment patterns for HR+, HER2– metastatic breast cancer (mBC) in real-world clinical practice. Methods A nationwide electronic health record–derived de-identified database was used to select patients diagnosed with HR+, HER2– mBC from January 1, 2011, to July 31, 2025. Patients had ≥2 documented visits after January 1, 2011, and structured clinical activity or visits ≤90 days from their metastatic diagnosis date. Results Among 23,044 patients, 8824 had ≥1 PIK3CA test. Test rates increased from 2011 to 2025 for patients starting first-, second-, or third-line treatment. In 2025, the testing rates any time prior to first-, second-, and third-line start dates were 20.2%, 61.6%, and 75.1%, respectively. Overall median time from mBC diagnosis to PIK3CA testing date was 4.8 months (range: 14.3 months [2019] to 2.3 months [2025]). Overall, 91.0% of PIK3CA tests were next-generation sequencing and 61.1% used tumor tissue. From 2019 onwards, 30.4% of patients with a positive test result received a PI3K or AKT inhibitor. Conclusion While PIK3CA mutation testing in patients with HR+, HER2– mBC has increased over time and shifted to earlier lines of therapy, overall rates of testing and subsequent use of targeted therapies remain low. This highlights potential gaps in both biomarker identification and uptake of PI3K or AKT inhibitors. Additionally, optimized processes are needed to reduce the time from diagnosis to testing. Specifically, prompt evaluation of patients whose disease recurs during or within 12 months of completing adjuvant endocrine therapy presents a critical opportunity to administer a biomarker-directed regimen (i.e., a combination of PI3K inhibitor, cyclin-dependent kinase 4/6 inhibitor, and endocrine therapy) with a demonstrated survival benefit.
Source: Frontiers in Oncology
Authors: Preet K. Dhillon(Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Eunice Kim(Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Writing – review & editing), Peter Lambert(Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing – review & editing), Anna Barulich(Conceptualization, Funding acquisition, Investigation, Resources, Supervision, Validation, Writing – review & editing), Emma Behan(Formal analysis, Methodology, Project administration, Resources, Validation, Writing – review & editing), Reva Basho(Conceptualization, Methodology, Supervision, Validation, Visualization, Writing – review & editing)
Institutions: Genentech, Ellison Medical Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, metastatic breast cancer, biomarker testing, PI3K inhibitors, AKT inhibitors, targeted therapy, treatment patterns, next-generation sequencing, endocrine therapy, CDK4/6 inhibitors, real-world clinical practice, health care costs
Open Access status: gold
Estimated APC paid: $3,801
Funder: Genentech
OpenAlex ID: W7235942704
